Vaxxinity has entered into a research collaboration with the University of Florida to advance the development of vaccines for neurodegenerative diseases, including Parkinson’s disease. Funded by a grant from the state of Florida, the partnership aims to advance Vaxxinity’s lead immunotherapy candidates, designed to prevent and manage…
A new dual-target, adaptive deep brain stimulation (DBS) protocol may offer more clinical benefits for patients than does traditional DBS for Parkinson’s disease, according to newly published data from a small clinical trial. DBS surgery — in which a small device is implanted in the brain to deliver…
Topline data from a Phase 3 clinical trial of buntanetap in early-stage Parkinson’s disease patients is expected soon, according to Annovis Bio, the therapy’s developer. Initially planned for the end of January, ongoing analysis to ensure “clean data” that are accurate and reliable was cited as the reason…
University Hospitals (UH) healthcare system in Cleveland, Ohio, has been named one of four new sites for a Global Parkinson’s Genetics Program (GP2) study that seeks to better understand Parkinson’s disease in Black people, with a focus on the disorder’s genetic basis. Improved knowledge of genetic variants…
Risvodetinib, an experimental therapy that Inhibikase Therapeutics is developing for Parkinson’s disease, was well tolerated both by healthy volunteers and Parkinson’s patients in a Phase 1 clinical trial. That’s according to the full results from the Inhibikase-funded work, detailed in a study titled “A Phase I, Randomized,…
Researchers from a university in Scotland were among the contributors to recent World Health Organization (WHO) guidelines outlining the most essential interventions in rehabilitation for 20 health conditions — including Parkinson’s disease — with high prevalence and elevated levels of associated disability. The WHO’s “Package of Interventions for Rehabilitation”…
Knight Therapeutics has entered into an exclusive license agreement with Amneal Pharmaceuticals giving it rights to apply for regulatory approval of IPX203 in Canada and across Latin America, and, if granted, to market the Parkinson’s disease treatment there. IPX203 is an investigational, extended-release oral formulation…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…
Being a caregiver for someone with Parkinson’s disease can be difficult, but for family members, providing care is not a burden, it’s a partnership, an opportunity to express their love. That’s according to interviews with 16 current and former Parkinson’s care partners. The findings were published in the…
A four-week exercise program to improve balance, directed by a smartphone app, can help older adults walk at a faster pace and correct their posture, a study has found, features that may help to prevent falls, a common complication of Parkinson’s disease. The app, being developed by scientists at…
Get regular updates to your inbox.